Asthma and corticosteroids "odi et amo": how to deal with it?

IF 3.1 Q2 ALLERGY
Frontiers in allergy Pub Date : 2026-04-13 eCollection Date: 2026-01-01 DOI:10.3389/falgy.2026.1772380
Luca Borsari, Laura Carbonieri, Luca M Verdini, Valentina Ruggieri, Bianca Beghe'
{"title":"Asthma and corticosteroids \"<i>odi et amo\":</i> how to deal with it?","authors":"Luca Borsari, Laura Carbonieri, Luca M Verdini, Valentina Ruggieri, Bianca Beghe'","doi":"10.3389/falgy.2026.1772380","DOIUrl":null,"url":null,"abstract":"<p><p>Asthma is a chronic, heterogeneous respiratory disease that affects more than 300 million individuals worldwide and is responsible for substantial morbidity, mortality and healthcare burden. Chronic airway inflammation plays a central role in symptom expression, disease progression, and response to therapy. Corticosteroids, both inhaled and systemic, are the cornerstone of asthma treatment. However, it is well known that the use and abuse of systemic corticosteroids is almost invariably associated to the development of significant acute and chronic adverse events. Epidemiological data report that despite the availability of new target therapy, e.g., biologics, in real practice systemic steroids are still overused, and in this review, we highlight strategies 1) to identify and screen patients at risk of developing corticosteroids adverse events and 2) to reduce them.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1772380"},"PeriodicalIF":3.1000,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111361/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/falgy.2026.1772380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Asthma is a chronic, heterogeneous respiratory disease that affects more than 300 million individuals worldwide and is responsible for substantial morbidity, mortality and healthcare burden. Chronic airway inflammation plays a central role in symptom expression, disease progression, and response to therapy. Corticosteroids, both inhaled and systemic, are the cornerstone of asthma treatment. However, it is well known that the use and abuse of systemic corticosteroids is almost invariably associated to the development of significant acute and chronic adverse events. Epidemiological data report that despite the availability of new target therapy, e.g., biologics, in real practice systemic steroids are still overused, and in this review, we highlight strategies 1) to identify and screen patients at risk of developing corticosteroids adverse events and 2) to reduce them.

哮喘和皮质类固醇“上瘾”:如何处理?
哮喘是一种慢性异质性呼吸系统疾病,影响全世界3亿多人,造成大量发病率、死亡率和医疗负担。慢性气道炎症在症状表达、疾病进展和对治疗的反应中起核心作用。吸入和全身的皮质类固醇是哮喘治疗的基石。然而,众所周知,全身皮质类固醇的使用和滥用几乎总是与重大急性和慢性不良事件的发生有关。流行病学数据报告,尽管有新的靶向治疗,如生物制剂,但在实际应用中,全身性类固醇仍被过度使用,在这篇综述中,我们强调的策略是1)识别和筛选有发生皮质类固醇不良事件风险的患者,2)减少它们。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书